)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Daxor
Daxor (DXR) investor relations material
Daxor Q2 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q2 2026 earnings summary29 Aug, 2026
Executive summary
Achieved FDA clearance for next-generation analyzer, secured a new patent, completed acquisition of Isotex Diagnostics, and executed a $9 million capital raise to support growth initiatives.
Focused on expanding commercial team and infrastructure, with kit sales up 16% year-over-year in H1 2026.
Transitioned regulatory reporting to reflect shift from investment company to medical diagnostics and technology operations.
Financial highlights
Net assets increased to $51.83 million as of June 30, 2026, up from $45.89 million at December 31, 2025.
Net asset value (NAV) per share was $8.88 at June 30, 2026, compared to $9.07 at year-end 2025.
Completed $9 million registered direct offering in January 2026 at $11.75 per share, accretive to NAV.
No outstanding debt as of June 30, 2026; retired $1.17 million in short-term debt during the period.
Stock-based compensation expense totaled $972,993 for the six months ended June 30, 2026.
Outlook and guidance
Expectation of accelerated kit sales growth in H2 2026 and into 2027 as expanded sales team ramps up.
Anticipate increased placements of next-generation BVA systems, with over fifteen indications of interest from hospitals and practices.
Continued investment in manufacturing capacity and inventory to support commercial expansion.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Daxor
- Shareholders will vote on director elections and auditor ratification; Feldschuh estate holds significant control.DXR
Proxy filing - Rapidly growing with FDA-cleared analyzers, proven clinical impact, and strong recurring revenue.DXRCorporate presentation
- Direct blood volume analysis drives clinical impact and commercial growth, with 45% revenue increase.DXRIAccess Alpha Virtual Best Ideas Spring Investment Conference 2026
- Operating revenue up 45% and net asset value per share climbs to $9.07, signaling strong growth.DXRQ4 2025
- Shareholders to elect six directors and ratify Bush & Associates, CPA as auditor for 2025.DXRProxy Filing
- Annual meeting to elect six directors and ratify Citrin Cooperman, LLP as auditor for 2024.DXRProxy Filing
- Revenue surged 116.5% as new FDA-cleared analyzers and recurring kit sales drive growth.DXRCorporate Presentation
- Net assets increased year-over-year, driven by higher operating division revenue and improved results.DXRQ2 2024
- Achieved strong revenue growth, cash flow break-even, and poised for major product launches.DXRQ4 2024
Next Daxor earnings date
Q3 202613 Nov, 2026
Daxor
Next Daxor earnings date
Q3 202613 Nov, 2026
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Daxor Corp is a biotechnology company that specializes in the manufacture of medical equipment, specifically blood volume analyzers. The company's flagship product is the BVA-100 blood volume analyzer, which is a diagnostic tool used to measure human blood volume. This product is complemented by Volumex, a diagnostic radiopharmaceutical containing iodinated I 131 albumins. Daxor's technology finds application across a wide range of medical and surgical conditions, including congestive heart failure, critical care, kidney failure, hypertension, renal failure, and more, serving hospitals, clinics, and physicians. The company is headquartered in Oak Ridge, Tennessee, but also has a significant presence in New York, New York, where its business operations are primarily based. Its shares are listed on the Nasdaq.